TP53 and B-cell chronic lymphocytic leukemia: The improved prognostic evaluation of patients affected with CLL entails genetic and cytogenetic markers, such as the mutation of tumor protein 53 (TP53), the deletion of the short arm of chromosome 17 (del17p) and the mutational status of immunoglobulin heavy chain variable region (IgHV).